Table 2. Patient demographics.
| Age (years) | Sex | Tumor size (cm) | NF2 a status | Laterality | Implant characteristics d | ||
|---|---|---|---|---|---|---|---|
| Prospective studies | |||||||
| Rooth et al 17 | United States | 49 | M | 1.5 | Spor b | NR c | MED-EL Synchrony Standard |
| 76 | F | 1.4 | Spor | NR | MED-EL Synchrony Standard | ||
| 59 | F | 1.5 | Spor | NR | MED-EL Synchrony Standard | ||
| 71 | M | 1 | Spor | NR | MED-EL Synchrony Standard | ||
| 49 | F | 0.4 | Spor | NR | MED-EL Synchrony Standard | ||
| 52 | F | 1.2 | Spor | NR | MED-EL Synchrony Standard | ||
| 44 | M | 0.5 | Spor | NR | MED-EL Synchrony Standard | ||
| Sanna et al 16 | Italy | Average of 50; range 33–71 | 8M, 5 F | 11 Intrameatal tumors, 2 extending into cerebellopontine angle | All 13 sporadic | All 13 NR | All 13 Cochlear Nucleus Freedom Contour Advance |
| Case studies | |||||||
| Ahsan et al 19 | United States | 53 | M | Intracanalicular | NF2+ | L | Cochlear Nucleus 24 Contour Advance |
| Aristegui and Denia 22 | Spain | 53 | M | 4 | NF2+ | L | MED-EL Combi 40+ |
| 45 | M | 1.2 | Spor | L | Cochlear Nucleus 24 Contour Advance | ||
| Carlson et al 13 | United States | 67 | M | 1.1 | NF2+ | NR | Cochlear Nucleus Contour Advance |
| Cruz and Vellutini 23 | Brazil | 23 | M | NR | NF2+ | L | NR |
| DeHart et al 14 | United States | 76 | M | 0.7 | Spor | R | MED-EL Synchrony Flex 28 |
| Tran Ba Huy et al 24 | France | 17 | F | <1 | NF2+ | L | Cochlear Nucleus Freedom |
| Kim et al 20 | Korea | 72 | F | 0.8 | Spor | L | MED-EL Sonata TI100 |
| 58 | M | 1.3 | Spor | L | MED-EL Concerto | ||
| Lloyd et al 18 | United Kingdom | 15 | M | 1.3 | NF2+ | L | Cochlear Nucleus Contour Advance |
| 36 | M | 1.5 | NF2+ | R | Cochlear Nucleus Freedom Contour Advance | ||
| 35 | F | 0.9 | NF2+ | R | Cochlear Nucleus Contour Advance | ||
| 30 | F | 1.1 | NF2+ | R | Cochlear Nucleus Slim Straight | ||
| Neff et al 25 | United States | 37 | F | NR | NF2+ | R | Cochlear Nucleus 24 Cochlear Advance |
| Dos Santos Neto et al 21 | Brazil | 43 | M | 0.2 | Spor | L | Cochlear Freedom Contour Advance |
| Ozdek et al 29 | Turkey | 57 | F | 1.2 | NF2+ | R | MED-EL Sonata |
| Plontke et al 28 | Germany | 38 | M | NR | Spor | NR | MED-EL Sonata |
| 39 | M | NR | Spor | NR | MED-EL Synchrony Flex28 | ||
| 25 | F | NR | Spor | NR | MED-EL Synchrony Flex28 | ||
| Vincenti et al 27 | Italy | 24 | F | 2 | NF2+ | NR | Cochlear Nucleus 24 Contour Advance |
| Zanetti et al 26 | Italy | 65 | F | NR | Spor | R | Cochlear Nucleus Contour Advance |
a
Neurofibromatosis type 2.
b
Sporadic.
c
Not reported.
d
Not all manufacturers, processors, or electrode arrays were detailed.
Only available data is reported.